Cytori Therapeutics receives Frost & Sullivan 2016 Technology Innovation Award
Cytori Therapeutics has received the Frost & Sullivan 2016 Technology Innovation Award in recognition of advancements made in the field of regenerative medicine for over a decade. Frost & Sullivan’s industry research and benchmarking analysis report that Cytori’s pioneering technology platform has become the leading technology to enable the research and practice of cellular therapies that harness the potential of stem and regenerative cells from adipose tissue.
Frost & Sullivan Industry Analyst Cecilia Van Cauwenberghe said, “Cytori is devoted to the development of cellular therapeutics as its Cell Therapy platform exploits the unique attributes of adipose derived stem cells for repair and healing. With a strong intellectual property portfolio of 89 patents, a broad spectrum of preclinical and clinical trials, and an extensive network of distribution and commercialization partners, we believe Cytori has become a global leader in the cell therapeutics market. We are pleased to confer this technology innovation award on Cytori Therapeutics.”
“Our team is honored to receive the 2016 technology innovation award,” said Dr. Marc H. Hedrick, president and chief executive officer of Cytori. “Frost & Sullivan is a leader in evaluating markets and forecasting business opportunity and this award is a clear recognition of the hard work and dedication of many—both our employees and the doctors and patients with whom we have worked over the years.”